SynthesisClinical research in cardiology : official journal of the German Cardiac Society2022
Device-related risk of atrial fibrillation after closure of patent foramen ovale: a systematic review and meta-analysis.
Synthesis in Clinical research in cardiology : official journal of the German Cardiac Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- New-onset atrial fibrillation after percutaneous patent foramen ovale closure: a meta-analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Pooled it
- Sex-Based Clinical Outcomes Following Percutaneous Closure of Patent Foramen Ovale.Journal of clinical medicine · 2026Article
- Efficacy and Safety of Percutaneous ASD Closure in Adults: Comparative Outcomes of Occluder Devices in a Single-Center Cohort.Journal of clinical medicine · 2025Article
- A multicenter analysis of implantable monitoring device-based diagnosis of supraventricular arrhythmia post patent foramen ovale closure: the OCCL-ILR study.Frontiers in cardiovascular medicine · 2025Article
- Arrhythmias Following Patent Foramen Ovale Closure: An Unsolved Enigma.Life (Basel, Switzerland) · 2024Review
- Article
- Heart-Stroke Team: A multidisciplinary assessment of patent foramen ovale-associated stroke.European stroke journal · 2024Article
- Incidence of Atrial Fibrillation or Arrhythmias After Patent Foramen Ovale Closure.Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- Review
- Patent Foramen Ovale and Cryptogenic Stroke: Integrated Management.Journal of clinical medicine · 2023Review
- Recent progress in patent foramen ovale and related neurological diseases: A narrative review.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) represents a frequent complication in patients after interventional closure of patent foramen ovale (PFO). We aimed to compare the incident rate and risk of AF between Amplatzer PFO and GORE (Helex and CARDIOFORM Septal Occluder) device by analyzing the data from randomized trials.
methodsWe included all randomized studies which reported the rate of AF after PFO closure using Amplatzer or GORE occluder in patients suffering cryptogenic stroke and compared the risk of AF between the two devices. PubMed and Cochrane library were searched for eligible studies published until July 2020.
resultsRate of all cases of incident AF from randomized trials with Amplatzer in the interventional group was 3.93% (30/763) vs. 1.46% (11/751) in the respective medical group (RR of 2.57, 95% CI 1.31-5.03, p = 0.006). The incidence of incident AF from randomized trial with GORE device was 6.57% (29/441) vs. 0.44% (1/223) in the respective medical group (RR of 14.66, 95% CI 2.01-106.95, p = 0.008). The p for interaction between the two devices regarding risk of AF was 0.10.
conclusionsThe results suggest lower risk expressed by lower rate of incident AF after PFO closure using Amplatzer PFO Occluder when compared with GORE Occluder. However, these findings are derived from secondary analyses and should be scrutinized using appropriate screening tool for AF following PFO closure in adequately powered randomized clinical trial with a head-to-head design that compares the two devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.